8-K: Tonix Pharmaceuticals Announces Positive Phase 3 Trial Data for Tonmya in Fibromyalgia, Showing Improvement in Depression and Other Symptoms

Tonix Pharmaceuticals' Tonmya demonstrated significant improvements in fibromyalgia symptoms, including depression, in a Phase 3 trial, with an NDA submission targeted for the second half of 2024.

Summary

• Tonix Pharmaceuticals presented data from the Phase 3 RESILIENT trial of Tonmya (TNX-102 SL) for fibromyalgia at the ASCP Annual Meeting.
• The trial showed that Tonmya improved depressive symptoms, as measured by the Beck Depression Inventory-II (BDI-II), with a statistically significant improvement over placebo at Week 14 (p=0.005) and an effect size of 0.27.
• Patients on Tonmya also showed improvements in several individual items on the Fibromyalgia Impact Questionnaire-Revised (FIQR), including depression (p < 0.001), anxiety (p = 0.001), sensitivity (p = 0.020), memory problems (p = 0.001), and energy (p < 0.001).
• The study also analyzed patients based on whether they experienced sensory adverse events (oral numbness, tingling, bitter aftertaste), and both groups showed significant improvement compared to placebo.
• The company believes these findings indicate that Tonmya has broad-spectrum activity against fibromyalgia symptoms and may improve the condition at the syndromal level.
• The New Drug Application (NDA) submission to the FDA for Tonmya is on track for the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a clear path to regulatory approval, suggesting a strong positive sentiment.

Positives

• Tonmya demonstrated a statistically significant reduction in depression severity, a key factor in fibromyalgia patients' quality of life.
• The drug showed broad-spectrum activity, improving not only pain but also other symptoms like anxiety, memory problems, and fatigue.
• The study showed a favorable tolerability profile with no new safety signals.
• Tonmya improved sexual functioning in females, which is a positive outcome compared to some other fibromyalgia treatments.
• The drug's sublingual formulation allows for rapid absorption and avoids first-pass hepatic metabolism.

Negatives

• Some patients experienced oral cavity adverse events such as oral numbness, tingling, and bitter aftertaste, although these were generally mild and temporary.
• The p-values for individual FIQR items were not corrected for multiplicity, which could inflate the significance of these results.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to regulatory approvals, clinical trial outcomes, and market competition.
• There is a risk that the FDA may not approve the NDA for Tonmya.
• The company may face challenges in commercializing Tonmya if approved.
• The company is dependent on third parties for research and development efforts.

Future Outlook

Tonix is on track to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.

Management Comments

• Dr. Lederman said, 'Although pain is the prototypic symptom in fibromyalgia and the validated FDA endpoint for the approval of a new drug, depression severity is also a prominent factor in the quality of life for fibromyalgia sufferers.'
• Dr. Lederman continued, 'In addition to the BDI-II score, in post hoc analyses several individual items on the Fibromyalgia Impact Questionnaire-Revised (FIQR) also improved in the Tonmya-treated group.'

Industry Context

The announcement is significant as it highlights a potential new treatment option for fibromyalgia, a condition with limited effective therapies. The focus on improving depression, a common comorbidity, is also noteworthy.

Comparison to Industry Standards

• The results of the RESILIENT trial are compared to other studies of antidepressants in mild depression, where benefits have been difficult to demonstrate.
• The study highlights that Tonmya's improvement in depression is particularly striking given the mild depression scores of the participants at baseline.
• The company notes that Tonmya's tolerability is an advantage over approved fibromyalgia pharmacotherapies with serotonergic reuptake inhibition, which often have sexual side effects.
• The study references a 2021 study that showed depressive symptoms had a higher correlation with impaired quality of life than any other symptom, including pain frequency and intensity.

Stakeholder Impact

• Shareholders may react positively to the positive clinical trial results and the progress towards NDA submission.
• Patients with fibromyalgia may benefit from a new treatment option that addresses both pain and depression.
• Employees of Tonix may be positively impacted by the company's progress and potential for commercial success.

Next Steps

• The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024.
• Tonix has scheduled a Type B pre-NDA meeting with FDA for the second quarter of 2024.

Key Dates

Keywords

Tonmya, TNX-102 SL, fibromyalgia, depression, clinical trial, RESILIENT trial, NDA, FDA, cyclobenzaprine, pain management, anxiety, sleep quality, fatigue